May 16, 2025 – In the latest episode of Oncopeptalks, David and Sofia discuss the key takeaways from the first quarter, Oncopeptides recent symposium at the COMy congress and what to look forward to in Q2.
May 16, 2025 – Oncopeptides CEO Sofia Heigis was recently interviewed by Richard Ramanius, equity analyst at Redeye, on the topic of the 2025 Q1 report.
Released May 15, 2025
CEO Sofia Heigis
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Interim Report Q2 2025 will be published August 21, 2025
April 16, 2025
The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.
Read more
March 13, 2025
In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.
Read moreApril 16, 2025
Oncopeptides announces the publication of new real-world data that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM).
Read moreApril 1, 2025
Oncopeptides today announces the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5.
Read moreFebruary 25, 2025
Oncopeptides AB today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus dexamethasone in patients with relapsed, refractory multiple myeloma (RRMM) has been published in the peer-reviewed journal European Journal of Haematology.
Read more
May 16, 2025
Oncopeptides CEO Sofia Heigis was recently interviewed by Richard Ramanius, equity analyst at Redeye, on the topic of the 2025 Q1 report.
Read moreMay 13, 2025
Oncopeptides AB will publish the report for the first quarter 2025, at 08:00 CET on May 15, 2025. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on May 15 at 09:00 CET.
Read more
Released April 28, 2025
CEO Sofia Heigis
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025
2025-05-22
Meeting
2025-07-22 - 2025-08-20
Other
2025-08-21
Report
”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.
